CRISPR Therapeutics AG (CRSP)
43.44
+0.30 (+0.68%)
USD |
NASDAQ |
Mar 24, 16:00
43.43
0.00 (0.00%)
After-Hours: 18:14
CRISPR Therapeutics Debt to Equity Ratio: 0.00 for Dec. 31, 2022
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | |
| December 31, 2015 | -1.318 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2018
--
Maximum
Mar 2018
--
Average
--
Median
Mar 2018
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals Inc | 0.00 |
| Intellia Therapeutics Inc | 0.00 |
| Beam Therapeutics Inc | 0.00 |
| Editas Medicine Inc | 0.00 |
| AC Immune SA | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.243B |
| Total Liabilities (Quarterly) | 367.58M |
| Shareholders Equity (Quarterly) | 1.875B |
| Current Ratio | 15.30 |